0.03
+4.00%
Close of 9 Nov 2026, in NZD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About BLIS Technologies
Its shares trade on NZX under the ticker BLT.NZ. It has been listed since 30 July 2001. In the fiscal year to 31 March 2025, it reported revenue of NZD 12.6m and net income of NZD 838,000. At that date it held total assets of NZD 14.3m and shareholders' equity of NZD 12.3m.
BLIS Technologies Ltd. engages in the development of healthcare products based on strains of bacteria that produce Bacteriocin activity. The company is headquartered in Dunedin, Otago. The company went IPO on 2001-07-30. The firm is also engaged in supply of healthcare ingredients and the manufacture of part and finished goods and food products for sale in domestic and international markets. The firm supplies BLIS-branded finished goods. The firm's products include BLIS K12 and BLIS M18, which are oral probiotics providing protection for ear, nose and throat health, halitosis (bad breath), gums and teeth health and immune support. The firm distributes its products through Stratum Nutrition in North America, NZPR Group in China, and Bluestone Pharma in Europe and Middle East. Its other BLIS branded products include Throat Guard EVERYDAY BLIS K12, Travel Guard BLIS K12, Fresh Breath Kit K12 and Toddler Protect BLIS K12 Powder for Toddlers.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 30 Jul 2001
- Employees
- 10
- Website
- blis.co.nz ↗
Leadership
Pay as last reported
- Peter FennessyNon-Executive Independent Chairman of the BoardNZD 40,000
- Mr. Scott JohnsonChief Executive Officer
- Mr. Geoffrey Philip PlunketDeputy Chairman of the Board, since 2018
- Mr. Richard WinghamChief Financial Officer
- Ms. Jennifer WalkerChief Revenue Officer
- Mr. Anthony OffenExecutive Deputy Chairman of the Board, since 2009NZD 28,750
- Ms. Anita JohansenDirector
- Ms. Aimee MccammonIndependent Director
- Dr. Barry RichardsonIndependent Director
- Mr. Alison StewartIndependent Director
- Mr. Graeme BoydNon-Executive Independent DirectorNZD 13,333
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- BLIS Technologies Ltd is a leading biotechnology company that specializes in probiotics.
- The company has a strong reputation for research and development, with a focus on innovative products.
- BLIS Technologies has a diverse product portfolio, catering to various health and wellness needs.
- The company has established strategic partnerships and collaborations to expand its market reach.
Weaknesses
- BLIS Technologies faces intense competition in the biotechnology industry, which may impact its market share.
- The company's dependency on research and development may lead to high costs and potential delays in product launches.
- BLIS Technologies operates primarily in the New Zealand market, limiting its global reach and potential customer base.
Opportunities
- Increasing consumer awareness and interest in probiotics present opportunities for BLIS Technologies to capitalize on the growing market demand.
- Expansion into international markets can help the company access a larger customer base and drive revenue growth.
- Strategic collaborations with healthcare professionals and industry leaders can enhance product development and market penetration.
Threats
- The regulatory environment in different countries may pose challenges for BLIS Technologies in terms of product approvals and compliance.
- Emerging competitors in the biotechnology industry can pose a threat to the company's market position and overall profitability.
- Changing consumer preferences and trends may impact the demand for probiotic products, requiring BLIS Technologies to adapt accordingly.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.